Home/Filings/4/0001104659-25-017618
4//SEC Filing

Sobel Alan D. 4

Accession 0001104659-25-017618

CIK 0001175151other

Filed

Feb 25, 7:00 PM ET

Accepted

Feb 26, 7:26 PM ET

Size

9.9 KB

Accession

0001104659-25-017618

Insider Transaction Report

Form 4
Period: 2025-02-24
Transactions
  • Exercise Out-of-Money

    Common Stock

    2025-02-24$1.13/sh+21,950$24,803145,757 total
  • Exercise Out-of-Money

    Series A Right Warrants (right to buy)

    2025-02-24$1.13/sh21,950$24,8030 total
    Exercise: $1.13From: 2025-01-17Exp: 2025-02-24Common Stock (21,950 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    2,000
Footnotes (4)
  • [F1]On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the Reporting Person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950. The Rights Offering closed on January 10, 2025 (the "Closing Date").
  • [F2]The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.
  • [F3]Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 3,300 RSUs granted on March 15, 2018, (b) 6,000 RSUs granted on February 24, 2017, (c) 5,000 RSUs granted on June 7, 2016, and (d) 55,000 RSUs granted on April 8, 2015 and (ii) 76,457 shares of Common Stock owned directly by the Reporting Person.
  • [F4]These shares are held in the Bernard Sobel Revocable Trust (the "Trust"), for which the Reporting Person is a trustee and a named beneficiary. Accordingly, the Reporting Person may be deemed the beneficial owner of the shares held in the Trust.

Issuer

Cytosorbents Corp

CIK 0001175151

Entity typeother

Related Parties

1
  • filerCIK 0001639386

Filing Metadata

Form type
4
Filed
Feb 25, 7:00 PM ET
Accepted
Feb 26, 7:26 PM ET
Size
9.9 KB